GlassScriptPhysician profile
Bernesta C Williams
NPI 1982804183
$1,206.81
in general payments reported to CMS, 2019-2025
14 companies · $624 in 2025
The $624 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $177 · 2024: $406 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,206.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $343.42 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $224.60 | 2024 | Ajovy, Austedo Xr |
| Genzyme Corporation | $148.43 | 2023 | |
| Pfizer INC. | $128.94 | 2024-2025 | |
| Biogen, INC. | $86.46 | 2025 | Tysabri, Vumerity |
| Livanova USA, INC. | $72.46 | 2023-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Amgen INC. | $42.53 | 2025 | Uplizna |
| Novartis Pharmaceuticals Corporation | $30.35 | 2025 | |
| Vanda Pharmaceuticals INC. | $25.75 | 2025 | Ponvory |
| Avadel Cns Pharmaceuticals, LLC | $24.49 | 2025 | Lumryz |
| Lundbeck LLC | $22.64 | 2025 | Vyepti |
| Neurocrine Biosciences, INC. | $20.44 | 2025 | |
| Celgene Corporation | $19.07 | 2025 | Zeposia |
| Inspire Medical Systems, INC. | $17.23 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernesta Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.